Wednesday 22 June 2022

US-based animal health company Zoetis Inc. (NYSE: ZTS) has closed the acquisition of US-based privately held petcare genetics company Basepaws, the company said.

Basepaws provides pet owners with genetic tests, analytics and early health risk assessments that can help manage the health, wellness and quality of care for their pets.

The acquisition will advance Zoetis' portfolio in the precision animal health space and will inform and shape its future pipeline of petcare innovations.

Financial terms of the agreement are not being disclosed.

Zoetis' R and D organization has brought innovation to petcare over the last 10 years in dermatology, parasiticides and pain, and the Basepaws database will help refine and inform the company's pipeline and future targets.

Basepaws is a petcare genetics company that builds early detection health risk tests based on genetic and microbiome data.

Basepaws is committed to companion animal health research, and it has the world's first at-home genetic testing platform for cats.

Founded in 2017 by Anna Skaya, the company is based in Los Angeles, CA.

Zoetis' portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries.